Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection
about
Anti-hepatitis C virus drugs and kidneyEffectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.New Therapies for Hepatitis C Virus Infection.Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET StudyInterferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world settingIdentification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem DomainLimited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study.Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the NetherlandsSofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from BelgiumPerformance of the New Aptima HCV Quant Dx Assay in Comparison to the Cobas TaqMan HCV2 Test for Use with the High Pure System in Detection and Quantification of Hepatitis C Virus RNA in Plasma or SerumNew perspectives for preventing hepatitis C virus liver graft infection.Retrospective analysis of hepatitis C infected patients treated through an integrated care model.Sofosbuvir and Simeprevir Combination Therapy for HCV Genotype 1 Infection: Results of a Single-Center VA Experience.Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.What's Important to the Patient? Informational Needs of Patients Making Decisions About Hepatitis C Treatment.High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4.Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.Interferon-free treatment for HCV-infected patients with decompensated cirrhosis.Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions.Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.Hepatitis C Treatment and Barriers to Eradication.Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs).Hepatitis C: efficacy and safety in real life.Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 PatientsEffectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients.Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD.Lupus-like Immune Complex-mediated Glomerulonephritis in Patients with Hepatitis C Virus Infection Treated with Oral, Interferon-free, Direct-acting Antiviral Therapy.Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.
P2860
Q28070279-C6184370-1FFC-45EE-9280-F9BBC9D63EABQ30841159-1BB72935-04BD-489D-A47E-A06D24A2259FQ33435950-D363E60B-BD50-41E8-8A46-0E411E7BCC67Q33560181-CB6EDD3E-C3A9-45CF-A9A6-B2651811F7E6Q33629092-E750B234-384A-4194-BDCA-7FE263518451Q33646482-70730D5E-5C58-4A68-914A-E24373771D3FQ36001172-C261E155-0A1B-40BC-99E4-5DE2BF95A187Q36123998-16359BE9-1EB3-4F01-9788-8DC5F0F404D2Q36145716-70AEA7DC-ABA0-4EDB-945E-60D6609C60D5Q36155257-E906E55F-4CB8-401B-AB34-D049133E4421Q36261373-48F923E8-955D-4D2C-9376-E476E2F7A3CEQ36734896-FF0442CC-EAC5-4816-B0B4-C4EBCDA4AEFBQ37015805-DA86A963-01EB-45B3-9745-484604602685Q37338952-BFAE60DB-FF65-41C5-A3AF-9292F44A3573Q37421505-E2B8247E-5DE9-453A-A714-A05DEA06A4E2Q38632730-B5D9ABE9-9B18-4E98-AB47-38FA0CF4FA40Q38692113-CFE40108-AA2F-4927-B99C-4A02227952AFQ38786027-B3C3CC07-C820-43BE-9948-83B7F689EA95Q38791337-36CFFDD2-BD78-48AA-84CB-C5DE1347977BQ38798462-C9FC2AA7-DC1A-46B8-ABCE-4C1922052E84Q38860200-2F7F2A1F-4510-46CD-A4D2-720C9AE24EEEQ38860565-D7360E5D-1E50-49E7-80A6-25F98C47539DQ38875903-A47161A8-311E-4CBB-9142-EEF5BA65E655Q38954096-26E7DDFF-0D13-4323-B553-DEDCB91C1A08Q38961563-7DA95A98-8F50-477D-AFA9-1B6937013CC5Q38985491-FD2ED717-D96E-4298-AC08-59B2EFB5303DQ39010715-18467847-4CFE-47E7-8C48-85B9591A654BQ39016874-FBEDA273-B6FB-4324-A5C0-B8EB75D79776Q39040719-F36355A0-C310-422E-A3D3-6AA927DFF627Q39058953-4D5CB9B4-A928-4962-939B-F989820847FDQ39099624-D43B3381-3FA5-41E8-BC85-68EB0D02D7E3Q39398874-2BA460EE-BB85-4AC9-B992-0B919339AD23Q39449507-99EDD5E7-20E0-4362-9CF2-924798FC67D7Q39599901-49C6A46E-876C-41DF-8627-36C044F82D75Q39609174-46E017BF-0C39-4F61-B542-107AEED47C31Q39690146-F333CDDA-07B9-42DB-9EEA-81FEB48CAF54Q39821108-A9C25633-527D-4F25-A9B0-761706910437Q40052523-A4976A9E-177D-462B-B0DD-4C5136C030E4Q40404776-18568687-B3A5-40BB-B4D8-76F107FF330AQ40484806-635C65A6-9C31-4B5F-BE87-D7FAEE655BE2
P2860
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Effectiveness of Simeprevir Pl ...... With HCV Genotype 1 Infection
@ast
Effectiveness of Simeprevir Pl ...... With HCV Genotype 1 Infection
@en
type
label
Effectiveness of Simeprevir Pl ...... With HCV Genotype 1 Infection
@ast
Effectiveness of Simeprevir Pl ...... With HCV Genotype 1 Infection
@en
prefLabel
Effectiveness of Simeprevir Pl ...... With HCV Genotype 1 Infection
@ast
Effectiveness of Simeprevir Pl ...... With HCV Genotype 1 Infection
@en
P2093
P2860
P50
P1433
P1476
Effectiveness of Simeprevir Pl ...... With HCV Genotype 1 Infection
@en
P2093
David R Nelson
Giuseppe Morelli
HCV-TARGET Study Group
Ira M Jacobson
Jama M Darling
Jordan J Feld
Joseph K Lim
Lynn M Frazier
Mark S Sulkowski
Michael W Fried
P2860
P304
P356
10.1053/J.GASTRO.2015.10.013
P407
P577
2015-10-21T00:00:00Z